Our Story

vision history team

Vision

Make physiology computable

SAMPLING's mission is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.

The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinical diagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.

The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc.). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.

History

From laboratory to clinical practice

Sampling Human is named for the changing paradigm of human biopsy, wherein standard tissue sampling is replaced by single cell diagnostics. The company was founded in 2016 to elevate the field beyond genetic analysis to routinely provide complex single cell data.

Thanks to the backing of a prominent central European investment group BPD partners a.s. (Draslovka, DIANA biotech, Nanuncio, Ginkgo Bioworks, Scipher Medicine, Q2Pharma) as well as support from top Czech research institutions UWB and IOCB, SAMPLING has in its short existence developed a portfolio of single cell technologies that redefine the implications of single cell data in practice.

With follow-on support from the Czech Ministry of Industry, and in collaboration with the Charles University Hospital, SAMPLING is currently validating these technologies in clinical workflows.

Team

Diverse team with a strong history

Laura Berne

Laura Berne

Scientist

  • Synthetic biology
Martin Cienciala

Martin Cienciala

Cofounder

Director of product development

Bob Englert

Bob Englert

COO

learn more

Jiri Fatka

Jiri Fatka

Software engineer

Pavel Fikar

Pavel Fikar

Director of automation

Daniel Georgiev

Daniel Georgiev

Cofounder

CEO/Director

learn more

Tomas Honzik

Tomas Honzik

Research associate

  • Machine learning
Hynek Kasl

Hynek Kasl

Cofounder

Director of engineering

Adriana Kasparkova

Adriana Kasparkova

Laboratory specialist

  • Synthetic biology
Lukas Kuhajda

Lukas Kuhajda

Research associate

  • Automation
Tereza Puchrova

Tereza Puchrova

Research associate

  • Synthetic biology
Zuzana Sramkova

Zuzana Sramkova

Laboratory manager

Leadership

Passionate leaders dedicated to company development

Daniel Georgiev

Daniel Georgiev

Cofounder

CEO/Director

learn more

Bob Englert

Bob Englert

COO

learn more

Martin Cienciala

Martin Cienciala

Cofounder

Director of product development

Hynek Kasl

Hynek Kasl

Cofounder

Director of engineering

Pavel Fikar

Pavel Fikar

Director of automation

Board

Engaged experts focused on proper governance

Larry Stambaugh

Larry Stambaugh

Chairman

learn more

Daniel Georgiev

Daniel Georgiev

Cofounder

CEO/Director

learn more

Martin Simonek

Martin Simonek

Director

learn more

Advisors

Leading field experts in single cell technologies, biotech, medicine, and global manufacturing

Pavel Bruzek

Pavel Bruzek

CEO at Draslovka

Chairman at BPD Partners

learn more

John Cumbers

John Cumbers

Founder/CEO at Synbiobeta

learn more

Peter Kuhn

Peter Kuhn

Dean’s Prof. of Biological Sciences at USC

Founder at Epic Sciences

learn more

Daniel Lysak

Daniel Lysak

Deputy head of the Department of hematology and oncology at CUH

learn more

Todd Peterson

Todd Peterson

Founder and principal at GenApex Biotech Consulting

learn more

Location

State of the art facilities

Sampling Human harnesses global innovation potential with state-of-the-art facilities in San Francisco and Prague. In addition, we are connected to a network of clinical institutions and core facilities that give us the power to engineer, discover, and validate single cell technologies and biomarkers with unprecedented speed and depth.